Emerging Companies & Venture Capital
Mark represents emerging companies, venture capital funds and corporate venture arms in private placements of debt and equity securities. He advises clients from startups to public companies on corporate matters, including corporate governance, contract preparation and negotiation, financing issues, restructurings, and ongoing strategic and transactional matters.
On significant venture capital investments, Mark has worked with clients including General Mills, Target, Xcel Energy, Zimmer Biomet, 3M Company, TT Capital Partners and UnitedHealth Group.
Mark leads FaegreBD's emerging companies and venture capital practice.
Mergers and Acquisitions
Mark represents buyers and sellers, strategic and private equity, in mergers, stock- and asset-based transactions and leveraged buyouts ranging from less than $200,000 to more than $1 billion.
Clients he has advised in significant M&A transactions include Proto Labs, Zimmer Biomet, Thomson Reuters, General Mills, UnitedHealth Group and Grey Mountain Partners.
Section 363 Bankruptcy Acquisitions
Mark also represents purchasers in Section 363 bankruptcy sales. Clients have included Baxter International and Wayzata Investment Partners.